# Santos Manes

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 73 papers | 5,705 citations | 41 h-index | 74 g-index |
| 74 ext. papers | 6,213 ext. citations | 9.8 avg, IF | 5.13 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 73 | The Importance of Mitochondrial Pyruvate Carrier in Cancer Cell Metabolism and Tumorigenesis. *Cancers*, **2021**, 13, | 6.6 | 11 |
| 72 | DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells **2021**, 9, | | 5 |
| 71 | Immunometabolism Modulation in Therapy. *Biomedicines*, **2021**, 9, | 4.8 | 2 |
| 70 | The Chemokine Receptor CCR5 Links Memory CD4 T Cell Metabolism to T Cell Antigen Receptor Nanoclustering.. *Frontiers in Immunology*, **2021**, 12, 722320 | 8.4 | 0 |
| 69 | SOD3 induces a HIF-2□dependent program in endothelial cells that provides a selective signal for tumor infiltration by T cells **2020**, 8, | | 15 |
| 68 | CCR5 deficiency impairs CD4 T-cell memory responses and antigenic sensitivity through increased ceramide synthesis. *EMBO Journal*, **2020**, 39, e104749 | 13 | 10 |
| 67 | Extracellular Superoxide Dismutase, the Endothelial Basement Membrane, and the WNT Pathway: New Players in Vascular Normalization and Tumor Infiltration by T-Cells. *Frontiers in Immunology*, **2020**, 11, 579552 | 8.4 | 5 |
| 66 | Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial. *Breast Cancer Research*, **2020**, 22, 124 | 8.3 | 7 |
| 65 | SOD3 boosts T cell infiltration by normalizing the tumor endothelium and inducing laminin-□. *OncoImmunology*, **2020**, 9, 1794163 | 7.2 | 3 |
| 64 | A flow cytometry-based method to screen for modulators of tumor-specific T cell cytotoxicity. *Methods in Enzymology*, **2020**, 631, 467-482 | 1.7 | 1 |
| 63 | PD-1 signaling affects cristae morphology and leads to mitochondrial dysfunction in human CD8 T lymphocytes **2019**, 7, 151 | | 48 |
| 62 | Age-related oxidative stress confines damage-responsive Bmi1 cells to perivascular regions in the murine adult heart. *Redox Biology*, **2019**, 22, 101156 | 11.3 | 4 |
| 61 | SOD3 improves the tumor response to chemotherapy by stabilizing endothelial HIF-2□*Nature Communications*, **2018**, 9, 575 | 17.4 | 28 |
| 60 | Diacylglycerol kinase □nactivation is an integral component of the costimulatory pathway that amplifies TCR signals. *Cancer Immunology, Immunotherapy*, **2018**, 67, 965-980 | 7.4 | 19 |
| 59 | Chemokine Receptor Signaling and the Hallmarks of Cancer. *International Review of Cell and Molecular Biology*, **2017**, 331, 181-244 | 6 | 53 |
| 58 | Notch-regulated miR-223 targets the aryl hydrocarbon receptor pathway and increases cytokine production in macrophages from rheumatoid arthritis patients. *Scientific Reports*, **2016**, 6, 20223 | 4.9 | 46 |
| 57 | p21 mediates macrophage reprogramming through regulation of p50-p50 NF-B and IFN-□*Journal of Clinical Investigation*, **2016**, 126, 3089-103 | 15.9 | 50 |

| | | | |
|---|---|---|---|
| 56 | APRIL promotes breast tumor growth and metastasis and is associated with aggressive basal breast cancer. *Carcinogenesis*, **2015**, 36, 574-84 | 4.6 | 26 |
| 55 | Filamin A interaction with the CXCR4 third intracellular loop regulates endocytosis and signaling of WT and WHIM-like receptors. *Blood*, **2015**, 125, 1116-25 | 2.2 | 18 |
| 54 | Type I phosphatidylinositol 4-phosphate 5-kinase homo- and heterodimerization determines its membrane localization and activity. *FASEB Journal*, **2015**, 29, 2371-85 | 0.9 | 12 |
| 53 | CX3CL1 promotes breast cancer via transactivation of the EGF pathway. *Cancer Research*, **2013**, 73, 4461-73 | 10.1 | 55 |
| 52 | Notch activation stimulates migration of breast cancer cells and promotes tumor growth. *Breast Cancer Research*, **2013**, 15, R54 | 8.3 | 89 |
| 51 | CX3CL1 at the crossroad of EGF signals: Relevance for the progression of ERBB2 breast carcinoma. *OncoImmunology*, **2013**, 2, e25669 | 7.2 | 9 |
| 50 | A lovastatin-elicited genetic program inhibits M2 macrophage polarization and enhances T cell infiltration into spontaneous mouse mammary tumors. *Oncotarget*, **2013**, 4, 2288-301 | 3.3 | 34 |
| 49 | APRIL and BAFF proteins increase proliferation of human adipose-derived stem cells through activation of Erk1/2 MAP kinase. *Tissue Engineering - Part A*, **2012**, 18, 852-9 | 3.9 | 22 |
| 48 | CCR5 in cancer immunotherapy: More than an "attractive" receptor for T cells. *OncoImmunology*, **2012**, 1, 106-108 | 7.2 | 22 |
| 47 | CCR5 as a potential target in cancer therapy: inhibition or stimulation?. *Anti-Cancer Agents in Medicinal Chemistry*, **2012**, 12, 1045-57 | 2.2 | 11 |
| 46 | Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. *Cancer Research*, **2011**, 71, 5455-66 | 10.1 | 79 |
| 45 | An isoform-specific PDZ-binding motif targets type I PIP5 kinase beta to the uropod and controls polarization of neutrophil-like HL60 cells. *FASEB Journal*, **2010**, 24, 3381-92 | 0.9 | 13 |
| 44 | Liver and brain imaging through dimercaptosuccinic acid-coated iron oxide nanoparticles. *Nanomedicine*, **2010**, 5, 397-408 | 5.6 | 57 |
| 43 | Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. *Molecular Cancer*, **2010**, 9, 196 | 42.1 | 119 |
| 42 | Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study. *Annals of Internal Medicine*, **2010**, 153, 281-8 | 8 | 53 |
| 41 | Dihydrosphingomyelin impairs HIV-1 infection by rigidifying liquid-ordered membrane domains. *Chemistry and Biology*, **2010**, 17, 766-75 | | 59 |
| 40 | Immunomodulatory and anti-inflammatory activities of statins. *Endocrine, Metabolic and Immune Disorders - Drug Targets*, **2009**, 9, 237-47 | 2.2 | 36 |
| 39 | Cytokine adsorption/release on uniform magnetic nanoparticles for localized drug delivery. *Journal of Controlled Release*, **2008**, 130, 168-74 | 11.7 | 36 |

| | | | |
|---|---|---|---|
| 38 | Statins induce regulatory T cell recruitment via a CCL1 dependent pathway. *Journal of Immunology*, **2008**, 181, 3524-34 | 5.3 | 74 |
| 37 | Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC. *Experimental Biology and Medicine*, **2008**, 233, 860-73 | 3.7 | 54 |
| 36 | CXCR4-CCR5: a couple modulating T cell functions. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 10101-6 | 11.5 | 165 |
| 35 | Filamin-A regulates actin-dependent clustering of HIV receptors. *Nature Cell Biology*, **2007**, 9, 838-46 | 23.4 | 146 |
| 34 | Establishment and maintenance of cell polarity during leukocyte chemotaxis. *Cell Adhesion and Migration*, **2007**, 1, 69-76 | 3.2 | 23 |
| 33 | Type I phosphatidylinositol 4-phosphate 5-kinase controls neutrophil polarity and directional movement. *Journal of Cell Biology*, **2007**, 179, 1539-53 | 7.3 | 58 |
| 32 | Gas1 is related to the glial cell-derived neurotrophic factor family receptors alpha and regulates Ret signaling. *Journal of Biological Chemistry*, **2006**, 281, 14330-9 | 5.4 | 43 |
| 31 | Orchestration of lymphocyte chemotaxis by mitochondrial dynamics. *Journal of Experimental Medicine*, **2006**, 203, 2879-86 | 16.6 | 237 |
| 30 | Lipid rafts in lymphocyte activation and migration. *Molecular Membrane Biology*, **2006**, 23, 59-69 | 3.4 | 73 |
| 29 | CD28 interaction with filamin-A controls lipid raft accumulation at the T-cell immunological synapse. *Nature Cell Biology*, **2006**, 8, 1270-6 | 23.4 | 124 |
| 28 | Mastering time and space: immune cell polarization and chemotaxis. *Seminars in Immunology*, **2005**, 17, 77-86 | 10.7 | 32 |
| 27 | T cell costimulation by chemokine receptors. *Nature Immunology*, **2005**, 6, 465-71 | 19.1 | 263 |
| 26 | PTEN regulates motility but not directionality during leukocyte chemotaxis. *Journal of Cell Science*, **2004**, 117, 6207-15 | 5.3 | 64 |
| 25 | Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. *Journal of Cell Science*, **2004**, 117, 1847-57 | 5.3 | 119 |
| 24 | Statins inhibit HIV-1 infection by down-regulating Rho activity. *Journal of Experimental Medicine*, **2004**, 200, 541-7 | 16.6 | 243 |
| 23 | Dynamic redistribution of raft domains as an organizing platform for signaling during cell chemotaxis. *Journal of Cell Biology*, **2004**, 164, 759-68 | 7.3 | 195 |
| 22 | Cholesterol domains regulate the actin cytoskeleton at the leading edge of moving cells. *Trends in Cell Biology*, **2004**, 14, 275-8 | 18.3 | 25 |
| 21 | The inner side of T cell lipid rafts. *Immunology Letters*, **2004**, 94, 247-52 | 4.1 | 53 |

| | | | |
|---|---|---|---|
| 20 | Differential requirements for DOCK2 and phosphoinositide-3-kinase gamma during T and B lymphocyte homing. *Immunity*, **2004**, 21, 429-41 | 32.3 | 202 |
| 19 | Novel interfering bifunctional molecules against the CCR5 coreceptor are efficient inhibitors of HIV-1 infection. *Molecular Therapy*, **2003**, 8, 475-84 | 11.7 | 21 |
| 18 | Pathogens: raft hijackers. *Nature Reviews Immunology*, **2003**, 3, 557-68 | 36.5 | 399 |
| 17 | From rafts to crafts: membrane asymmetry in moving cells. *Trends in Immunology*, **2003**, 24, 320-6 | 14.4 | 71 |
| 16 | CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. *Journal of Experimental Medicine*, **2003**, 198, 1381-9 | 16.6 | 114 |
| 15 | Quantitative determination of tumor cell intravasation in a real-time polymerase chain reaction-based assay. *Clinical and Experimental Metastasis*, **2002**, 19, 313-8 | 4.7 | 37 |
| 14 | Specific SHP-2 partitioning in raft domains triggers integrin-mediated signaling via Rho activation. *Journal of Cell Biology*, **2002**, 157, 277-89 | 7.3 | 79 |
| 13 | Blocking of HIV-1 infection by targeting CD4 to nonraft membrane domains. *Journal of Experimental Medicine*, **2002**, 196, 293-301 | 16.6 | 83 |
| 12 | A role for chemokine receptor transactivation in growth factor signaling. *EMBO Reports*, **2001**, 2, 151-6 | 6.5 | 73 |
| 11 | The collagen receptor DDR2 regulates proliferation and its elimination leads to dwarfism. *EMBO Reports*, **2001**, 2, 446-52 | 6.5 | 209 |
| 10 | Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. *Annual Review of Immunology*, **2001**, 19, 397-421 | 34.7 | 302 |
| 9 | Membrane raft microdomains in chemokine receptor function. *Seminars in Immunology*, **2001**, 13, 147-57 | 10.7 | 52 |
| 8 | Insulin-like Growth Factor Axis Elements in Breast Cancer Progression **2001**, 107-166 | | |
| 7 | Cells on the move: a dialogue between polarization and motility. *IUBMB Life*, **2000**, 49, 89-96 | 4.7 | 37 |
| 6 | Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. *EMBO Reports*, **2000**, 1, 190-6 | 6.5 | 305 |
| 5 | Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9. *Endocrinology*, **1999**, 140, 1657-64 | 4.8 | 89 |
| 4 | The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. *Journal of Biological Chemistry*, **1999**, 274, 6935-45 | 5.4 | 143 |
| 3 | Membrane raft microdomains mediate front-rear polarity in migrating cells. *EMBO Journal*, **1999**, 18, 6211-20 | 13 | 278 |

| | | | |
|---|---|---|---|
| 2 | Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. *Journal of Biological Chemistry*, **1997**, 272, 25706-12 | 5.4 | 162 |
| 1 | CCR5 deficiency impairs CD4+ T cell memory responses and antigenic sensitivity through increased ceramide synthesis | | 1 |